美国食品药品监督管理局（FDA）已正式批准拜玛林制药（Biomarin Pharmaceutical）旗下药物Palynziq®（Pegvaliase-Pqpz）用于治疗12岁及以上的苯丙酮尿症（PKU）青少年患者。这一批准标志着该药物适用人群的扩展，为更年轻的PKU患者提供了新的治疗选择。
美国食品药品监督管理局（FDA）已正式批准拜玛林制药（Biomarin Pharmaceutical）旗下药物Palynziq®（Pegvaliase-Pqpz）用于治疗12岁及以上的苯丙酮尿症（PKU）青少年患者。这一批准标志着该药物适用人群的扩展，为更年轻的PKU患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.